



British Menopause Society, London, UK

Correspondence to: H Hamoda

haitham.hamoda@nhs.net

Cite this as: *BMJ* 2022;377:e01425<http://dx.doi.org/10.1136/bmj.01425>

Published: 15 June 2022

Looking at HRT in perspective

Helping women make informed choices

Haitham Hamoda, Sara Moger

With average life expectancy in developed countries now exceeding 80, many women will live around a third of their lives after the menopause and may experience related problematic symptoms for several years. This can have a detrimental effect on quality of life, including personal relationships and working life.^{1,2}

More than 75% of those experiencing the menopause report symptoms, and over 25% describe their symptoms as severe. Average duration of symptoms is seven years, and a third of women have symptoms for longer. The menopause can also have a detrimental effect on bone and cardiovascular health.³

For those seeking help, the National Institute of Health and Care Excellence (NICE) and others^{1,2,4} recommend an individualised and comprehensive approach that includes advice on exercise, optimising weight, stopping smoking, and reducing alcohol consumption as well as management options such as hormone replacement therapy (HRT). The latest evidence for women considering HRT is reassuring, including for all-cause mortality. Assessing the effect on all-cause mortality is particularly relevant as it looks at death as the endpoint for both the benefits and risks.

The main indication for HRT remains control of problematic menopausal symptoms and improving quality of life. Evidence from randomised trials shows clear benefits in this context,⁵ and no arbitrary limits should be placed on duration of use.^{1,2,4} HRT may help relieve short term cognitive symptoms related to the menopause, but this should be clearly differentiated from dementia prevention. Evidence does not support use of HRT to reduce the risk of dementia.^{1,2,4,6,7}

The risk of breast cancer associated with HRT remains a concern for many women. Current evidence suggests that oestrogen only formulations are associated with little or no change in the risk of breast cancer, while combined HRT (oestrogen plus a progestogen) can be associated with an increased risk. This appears duration dependent and may vary with the type of progestogen used.¹⁸⁻¹⁰ However, the risk is low (absolute excess risk of breast cancer over 10 years is 3-7/1000 women taking combined HRT for up to 5 years),¹⁰ particularly compared with risks associated with other modifiable risk factors such as obesity and alcohol intake.

Benefits

Risk of breast cancer should be placed in the context of the overall benefits from HRT. For most women with problematic symptoms the benefits are likely to outweigh the risks.^{1,2,4,8-10} NICE's review of trials and

cohort studies shows that HRT significantly protects against fragility fractures related to osteoporosis and helps prevent osteoporosis in both spine and hip.^{1,2,4}

Furthermore, evidence from a Cochrane review of randomised trials and from large observational studies in symptomatic menopausal women suggests that HRT (with or without progestogen) started before the age of 60 or within 10 years of the menopause may protect against cardiovascular disease. Timing of commencement is critical to this effect, often referred to as the cardiovascular timing hypothesis.^{1,2,4,11-13}

In an analysis of placebo controlled trials in a total of 8311 women, the Cochrane review noted a significant reduction in coronary heart disease, including cardiovascular mortality, among women who started HRT before the age of 60 (10/1000 v 18/1000 with placebo; relative risk 0.52, 95% CI 0.29 to 0.96). An additional analysis in 9088 women found a significant reduction in all-cause mortality (16/1000 v 22/1000 with placebo; 0.70, 0.52 to 0.95).¹¹

This protective effect was not seen among women who started HRT more than 10 years after the menopause in either the long term follow-up of the Women's Health Initiative trials (WHI) or the Cochrane analysis. Notably, there was no increase in risk of cardiovascular events, cardiovascular mortality, or all-cause mortality.¹¹

A pooled analysis of the WHI trials found a significant reduction in all-cause mortality during the intervention phase among women aged 50 to 59 years who took HRT for an average of 5.6 years (combined HRT) or 7.2 years (oestrogen only) compared with placebo in a study with a median of 18 years' follow-up (hazard ratio 0.69, 95% CI 0.51 to 0.94).¹⁴

An analysis of long term follow-up data of 9939 women aged 50-79 from WHI also reported a significant reduction in all-cause mortality among 1129 women aged 50-59 who took oestrogen-only HRT after bilateral salpingo-oophorectomy compared with those who received placebo (hazard ratio 0.68, 0.48 to 0.96).¹³

A systematic review and meta-analysis of observational studies and randomised trials noted a significant reduction in all-cause mortality in women who started HRT before the age of 60 within the observational studies. However, no significant reduction was noted in the subgroup analysis of randomised trials.¹⁵

Finally, a systematic review and meta-regression analysis of 31 randomised trials found that women who started HRT under the age of 60 had lower odds of coronary heart disease (odds ratio 0.61, 0.37 to

1.00), cardiovascular mortality (0.61, 0.37 to 1.00), and all-cause mortality (0.72, 0.57 to 0.91) compared with controls or those not taking HRT.¹⁶

The balance of benefits and risks, however, does not support use of HRT for primary or secondary prevention of disease, and international guidance recommends against use of HRT without a clear indication.^{2 4}

Access to accurate information about the menopause, and to help and support from reliable sources, makes women better placed to manage the menopause transition and improve their quality of life. Healthcare providers should take an individualised approach to assessment and empower women to make informed decisions based on unbiased, evidence based information applied effectively. Nobody should be suffering in silence or feel that the effect of the menopause is not adequately recognised.

Competing interests: *The BMJ* has judged that there are no disqualifying financial ties to commercial companies. The authors declare no other interests. Further details of *The BMJ* policy on financial interests are here: <https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf>.

Provenance and peer review: Commissioned; not externally peer reviewed.

- 1 National Institute for Health and Care Excellence. *Menopause: diagnosis and management*. NICE, 2015.
- 2 Hamoda H, Panay N, Pedder H, Arya R, Savvas M. The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. *Post Reprod Health* 2020;26:181-209. doi: 10.1177/2053369120957514. pmid: 33045914
- 3 Avis NE, Crawford SL, Greendale G, et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med* 2015;175:531-9. doi: 10.1001/jamainternmed.2014.8063 pmid: 25686030
- 4 Baber RJ, Panay N, Fenton AIMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric* 2016;19:109-50. doi: 10.3109/13697137.2015.1129166 pmid: 26872610
- 5 MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. *Cochrane Database Syst Rev* 2004;4:CD002978. doi: 10.1002/14651858.CD002978.pub2 pmid: 15495039
- 6 Shumaker SA, Legault C, Kuller L, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004;291:2947-58. doi: 10.1001/jama.291.24.2947 pmid: 15213206
- 7 Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. *Neurology* 2016;87:699-708. doi: 10.1212/WNL.0000000000002980. pmid: 27421538
- 8 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet* 2019;394:1159-68. doi: 10.1016/S0140-6736(19)31709-X pmid: 31474332
- 9 Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. *JAMA* 2020;324:369-80. doi: 10.1001/jama.2020.9482 pmid: 32721007
- 10 Marsden J, Pedder H. The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis. *Post Reprod Health* 2020;26:126-35. doi: 10.1177/2053369120956636. pmid: 32997592
- 11 Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev* 2015;3:CD002229. doi: 10.1002/14651858.CD002229.pub4 pmid: 25754617
- 12 Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. *Menopause* 2015;22:976-83. doi: 10.1097/GME.0000000000000450. pmid: 25803671
- 13 Manson JE, Aragaki AK, Bassuk SS, et al. WHI Investigators. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. *Ann Intern Med* 2019;171:406-14. doi: 10.7326/M19-0274. pmid: 31499528
- 14 Manson JE, Aragaki AK, Rossouw JE, et al. WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. *JAMA* 2017;318:927-38. doi: 10.1001/jama.2017.11217 pmid: 28898378
- 15 Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. *Sci Rep* 2020;10:20631. doi: 10.1038/s41598-020-77534-9. pmid: 33244065

- 16 Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke. *Int J Cardiol Heart Vasc* 2019;22:123-31. doi: 10.1016/j.ijcha.2019.01.001. pmid: 30705938